Literature DB >> 29979199

Use of Hydroxocobalamin (Vitamin B12a) in Patients With Vasopressor Refractory Hypotension After Cardiopulmonary Bypass: A Case Series.

Sarah Armour1, Trygve K Armour1, William R Joppa2, Simon Maltais3, James A Nelson1, Erica Wittwer1.   

Abstract

Hydroxocobalamin (vitamin B12a) is an emerging treatment for vasoplegic syndrome (VS) associated with cardiopulmonary bypass (CPB). Given its cost and scarcity, an institutional guideline for its use as a rescue treatment in cases of suspected VS was developed. Hemodynamic variables and vasopressor requirements were reviewed for a series of 24 post-CPB patients who received B12a. Favorable changes in hemodynamic parameters and vasopressor requirements were seen after B12a administration although guideline criteria for VS were inconsistently met. These findings support the continued study of B12a in patients with CPB-associated VS.

Entities:  

Year:  2019        PMID: 29979199     DOI: 10.1213/ANE.0000000000003648

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  4 in total

Review 1.  Vasoplegia after cardiopulmonary bypass: A narrative review of pathophysiology and emerging targeted therapies.

Authors:  Theresa J Barnes; Maxwell A Hockstein; Craig S Jabaley
Journal:  SAGE Open Med       Date:  2020-06-25

2.  Extended Duration Infusion of Hydroxocobalamin for Vasoplegic Rescue in Septic Shock.

Authors:  Harrison J Gerdes; Troy G Seelhammer; Scott Nei; Juan Diaz Soto; Christoph G Nabzdyk
Journal:  Cureus       Date:  2021-02-17

3.  Hydroxocobalamin in Refractory Septic Shock: A Retrospective Case Series.

Authors:  Alicia J Sacco; Cody A Cunningham; Heidi E Kosiorek; Ayan Sen
Journal:  Crit Care Explor       Date:  2021-04-26

4.  High-Dose Hydroxocobalamin for Refractory Vasoplegia Post Cardiac Surgery.

Authors:  Marek A Bak; Julian A Smith; Brendan Murfin; Yi Chen
Journal:  Cureus       Date:  2022-08-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.